Sep 22 2009
Rochester Medical Corporation (Nasdaq: ROCM) today announced that the Company's FemSoft(R) Insert has been approved for inclusion in Part IX of the UK Drug Tariff as a prescription product which is reimbursable.
There are no other products listed in the Drug Tariff specifically for managing female stress urinary incontinence, and the Company believes that for many women this will be a very welcome addition that offers a discreet, non-surgical, odor-free, secure, and safe alternative to absorbents.
FemSoft(R) Inserts are particularly effective in situations where leakage occurs during certain physical activities such as exercise, coughing, laughing, or sneezing.
Hugh McLeod, General Manager of the U.K. business commented that this represents a significant opportunity for Rochester Medical and will enhance the Company's position as the leading worldwide innovator and marketer of silicone continence care devices.
He noted that the FemSoft(R) Insert product line fits perfectly alongside Rochester Medical's current portfolio of catheters for intermittent self-catheterization and will be marketed through the same customer base of Urology Nurse Specialists and Continence Nurse Specialists.
Commenting on the news, Anthony J. Conway Rochester Medical CEO and President said, "This is excellent news for women in the United Kingdom and also great news for Rochester Medical. We believe the FemSoft(R) Insert provides an elegant non-surgical, comfortable, and dry alternative to absorbents. Earlier this year we announced that U.S. Medicare has given preliminary reimbursement approval to the FemSoft Insert, and we expect final confirmation in the near future. In both the U.K. and U.S. we expect implementation of the reimbursement to begin in January 2010, and we are making sales and marketing preparations accordingly."